New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 2, 2013
09:08 EDTSTEMStemCells receives FDA authorization of IND for spinal cord injury
StemCells announced that the FDA has authorized the company's Investigational New Drug, or IND, application for clinical testing of the company's proprietary HuCNS-SC human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
10:04 EDTSTEMStemCells reports top line results for Phase I/II study in dry AMD
Subscribe for More Information
June 22, 2015
07:05 EDTSTEMStemCells data likely to be positive, says Cantor
Subscribe for More Information
June 18, 2015
09:04 EDTSTEMOn The Fly: Pre-market Movers
Subscribe for More Information
08:07 EDTSTEMStemCells Phase II Pathway Study approved by Health Canada
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use